Balancing Intellectual Property and Access to Medicines
Author Information
Author(s): Martin Greg, Sorenson Corinna, Faunce Thomas
Primary Institution: World Cancer Research Fund
Hypothesis
How can the TRIPS agreement be balanced to protect public health while respecting intellectual property rights?
Conclusion
The TRIPS agreement needs to be implemented in a way that prioritizes public health and access to essential medicines.
Supporting Evidence
- About one-third of the world's population does not have access to essential medicines.
- 90 percent of the burden for global disease is carried by a population for whom only three percent of the R&D expenditure is directed.
- Countries can use compulsory licensing to lower prices for essential medicines.
Takeaway
This article talks about how some countries are trying to make sure everyone can get important medicines, even if they are expensive. It suggests that rules about patents should be fairer to help people in need.
Potential Biases
The influence of pharmaceutical companies and trade agreements may bias the implementation of TRIPS provisions.
Limitations
The editorial does not provide specific data or empirical evidence to support its claims.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website